Evidence map›Paper›PMID 25086237›Full record

ArticleJournal of inorganic biochemistry2014

Novel amphiphilic cationic porphyrin and its Ag(II) complex as potential anticancer agents.

Artak Tovmasyan, Nelli Babayan, David Poghosyan, Kristine Margaryan, Boris Harutyunyan, Rusanna Grigoryan, Natalia Sarkisyan, Ivan Spasojevic, Suren Mamyan, Lida Sahakyan and 3 more

Abstract read
In one paragraph

Article in Journal of inorganic biochemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. The Interactions of HBiomolecules · 2021
    Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Artak TovmasyanDepartment of Chemistry, Pharmacy Faculty, Yerevan State Medical University, 2 Koryun Str., Yerevan 0025, Armenia. Electronic address: artak.tovmasyan@duke.edu.
Nelli BabayanDepartment of Genetics and Cytology, Yerevan State University, 1 Alex Manoogian Str., Yerevan 0025, Armenia; Institute of Molecular Biology, NAS RA, 7 Hasratyan Str., Yerevan 0014, Armenia.
David PoghosyanInstitute of Molecular Biology, NAS RA, 7 Hasratyan Str., Yerevan 0014, Armenia.
Kristine MargaryanDepartment of Genetics and Cytology, Yerevan State University, 1 Alex Manoogian Str., Yerevan 0025, Armenia.
Boris HarutyunyanDepartment of Chemistry, Pharmacy Faculty, Yerevan State Medical University, 2 Koryun Str., Yerevan 0025, Armenia.
Rusanna GrigoryanInstitute of Molecular Biology, NAS RA, 7 Hasratyan Str., Yerevan 0014, Armenia.
Natalia SarkisyanInstitute of Molecular Biology, NAS RA, 7 Hasratyan Str., Yerevan 0014, Armenia.
Ivan SpasojevicDepartment of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Suren MamyanMolecular Structure Research Center, NAS RA, 26 Azatutian Str., Yerevan 0014, Armenia.
Lida SahakyanDepartment of Chemistry, Pharmacy Faculty, Yerevan State Medical University, 2 Koryun Str., Yerevan 0025, Armenia.
Rouben AroutiounianDepartment of Genetics and Cytology, Yerevan State University, 1 Alex Manoogian Str., Yerevan 0025, Armenia.
Robert GhazaryanDepartment of Chemistry, Pharmacy Faculty, Yerevan State Medical University, 2 Koryun Str., Yerevan 0025, Armenia. Electronic address: ghrob@mail.ru.
Gennadi GasparyanDepartment of Genetics and Cytology, Yerevan State University, 1 Alex Manoogian Str., Yerevan 0025, Armenia; Institute of Molecular Biology, NAS RA, 7 Hasratyan Str., Yerevan 0014, Armenia.
National Academy of Sciences of Armenia · AMYerevan State Medical University · AMYerevan State University · AMDuke University Hospital · USInstitute of Molecular Biology · AM

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
NCI NIH HHS P30 CA014236
6 · The paper itself

Abstract

In the present study we have synthesized a novel amphiphilic porphyrin and its Ag(II) complex through modification of water-soluble porphyrinic structure in order to increase its lipophilicity and in turn pharmacological potency. New cationic non-symmetrical meso-substituted porphyrins were characterized by UV-visible, electrospray ionization mass spectrometry (ESI-MS), (1)H NMR techniques, lipophilicity (thin-layer chromatographic retention factor, Rf), and elemental analysis. The key toxicological profile (i.e. cytotoxicity and cell line- (cancer type-) specificity; genotoxicity; cell cycle effects) of amphiphilic Ag porphyrin was studied in human normal and cancer cell lines of various tissue origins and compared with its water-soluble analog. Structural modification of the molecule from water-soluble to amphiphilic resulted in a certain increase in the cytotoxicity and a decrease in cell line-specificity. Importantly, Ag(II) porphyrin showed less toxicity to normal cells and greater toxicity to their cancerous counterparts as compared to cisplatin. The amphiphilic complex was also not genotoxic and demonstrated a slight cytostatic effect via the cell cycle delay due to the prolongation of S-phase. As expected, the performed structural modification affected also the photocytotoxic activity of metal-free amphiphilic porphyrin. The ligand tested on cancer cell line revealed a dramatic (more than 70-fold) amplification of its phototoxic activity as compared to its water-soluble tetracationic metal-free analog. The compound combines low dark cytotoxicity with 5 fold stronger phototoxicity relative to Chlorin e6 and could be considered as a potential photosensitizer for further development in photodynamic therapy.

Indexed as

Antineoplastic AgentsCationsCell Line, TumorDrug Screening Assays, AntitumorHumansPorphyrinsProton Magnetic Resonance SpectroscopySilverSpectrometry, Mass, Electrospray IonizationAntineoplastic AgentsCationsPorphyrinsSilverAg porphyrinAmphiphilic porphyrinAnticancer activityCytotoxicityGenotoxicityPhotosensitizer

Identifiers

PMID25086237
PMCPMC4527612
OpenAlexW2000162183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.